Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Cancer Res. 2021 Sep 30;81(23):6018–6028. doi: 10.1158/0008-5472.CAN-21-0030

Figure 1. Engineered SALL4-partial dependency in SALL4-negative cancer cells.

Figure 1.

(A) Western blot of SALL4 protein in GFP control (H1299-GFP) or exogenous SALL4-expressing H1299 (H1299-SALL4) cells 48 hours after transfection of shRNA negative control (NC) or SALL4 shRNA (SALL4), β-actin was used as normalized control. (B) Cell viability of GFP control or SALL4-expressing H1299 cells after the indicated treatments. (C) Flow cytometry plots showing Annexin/PI staining of GFP control or SALL4-expressing H1299 cells after the indicated treatments. (D) Percent apoptotic (Annexin+) and dead cells (Annexin− /PI+) from (C). (E) Western blot of SALL4 protein in H661 cells 48 hours after transfection of negative control sh-NC or SALL4 shRNA. β-actin was used as normalized control. (F) Cell viability of H661 cells after indicated treatment. (G) Flow cytometry plots showing Annexin/PI following the indicated treatment. (H) Percent apoptotic and dead cells from (G). (I) Representative images of tumors harvested from mice 30 days following sub-cutaneous injection of H1299 cells expressing the indicated vectors. (J) Tumor weight and (K) body weight from indicated groups (N=5). n.s. means P>0.05, *P<0.05, **P<0.01, ***P<0.001, N=3.